A class action lawsuit has been filed against Embecta Corp. and certain senior executives for securities fraud. The suit alleges the company misrepresented the strength of its insulin pen needle product category while facing significant competition and overall market softness. On May 5, 2026, Embecta announced disappointing Q2 2026 results below guidance due to share loss within its pen needle product category, mostly from a single customer, and reported a decline in insulin pen prescriptions. The news caused Embecta common stock to drop 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026. Investors have until August 17, 2026 to seek lead plaintiff appointment in the case pending in the U.S. District Court for the District of New Jersey.
Embecta CorpSecurities fraud lawsuit alleging misrepresentations about insulin pen needle product category strength.